Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menstrual Bleeding Clear all
Completed No phase listed Observational Accepts healthy volunteers

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

NCT03182140
View directory record Official record
Conditions
Contraception
Interventions
Kyleena
Drug
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 23, 2026, 11:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

NCT01581905
View directory record Official record
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Copper IUD Treatment Observation Study

NCT02519231
View directory record Official record
Conditions
Menorrhagia
Interventions
Naproxen, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional Results available

A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding

NCT02842736
View directory record Official record
Conditions
Menorrhagia
Interventions
Cerene(R) Cryotherapy Device
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

NCT02829957
View directory record Official record
Conditions
Venous Thromboembolism, Menstruation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial

NCT00350480
View directory record Official record
Conditions
Uterine Hemorrhage, Menorrhagia
Interventions
Provera, Combination Birth Control pills
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 23, 2026, 11:26 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

NCT04205266
View directory record Official record
Conditions
Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions
Ferumoxytol, Ferrous Sulfate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 23, 2026, 11:26 AM EDT
Withdrawn Phase 4 Interventional

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

NCT03325868
View directory record Official record
Conditions
Adenomyosis, Heavy Uterine Bleeding, Dysmenorrhea
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03886220
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

NCT00614406
View directory record Official record
Conditions
Ovulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days), Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Interventions
Celebrex, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Treatment and Management of Women With Bleeding Disorders

NCT00111215
View directory record Official record
Conditions
Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions
Tranexamic Acid, Desmopressin Acetate
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2007 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Hysteroscopic Assessment of Fallopian Tubal Patency

NCT02005263
View directory record Official record
Conditions
Infertility, Menorrhagia
Interventions
Salpingography
Procedure
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 23, 2026, 11:26 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 23, 2026, 11:26 AM EDT
Not listed No phase listed Observational

Post Approval NovaSure Essure Labeling Study

NCT01934244
View directory record Official record
Conditions
Menorrhagia
Interventions
NovaSure Endometrial Ablation
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Arvada, Colorado • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

NCT06136104
View directory record Official record
Conditions
Healthy, Premenstrual Dysphoric Disorder, Premenstrual Syndrome
Interventions
Mixhers HERTIME, Placebo
Dietary Supplement
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

NCT04425577
View directory record Official record
Conditions
Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions
Transabdominal Ultrasound
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 22 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Vaginal Bromocriptine for Treatment of Adenomyosis

NCT01821001
View directory record Official record
Conditions
Adenomyosis
Interventions
Vaginal Bromocriptine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 23, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

NCT00700128
View directory record Official record
Conditions
Migraines, Bleeding, Spotting
Interventions
frovatriptan, placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 23, 2026, 11:26 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 23, 2026, 11:26 AM EDT